Olive AI reportedly raised around $900 million, shut down and sold its assets in October 2023, and left hospitals and provider groups reassessing revenue cycle automation. Many mid market provider groups now need a replacement that fits their workflow and budget.
CloudNSite builds healthcare AI around the exact revenue cycle bottlenecks your team is trying to remove, then works with your current systems.
Hospitals and provider groups that need focused RCM automation without enterprise platform lock in
Waystar became one successor path for some Olive customers after buying Olive's data clearinghouse and digital insurance determination units for about $10 million, and it already serves large healthcare enterprises.
Large health systems that already have Waystar relationships and enterprise budget
An internal engineering and operations team builds custom automation around your billing workflows, data access rules, and reporting needs.
Organizations with internal engineering depth, patient timelines, and a clear long term build plan
Consider these factors when making your decision.
Prior auth, denials, attachments, and status checks create very different workloads. Start with the one bottleneck that is costing the most staff time or delaying cash the most.
Enterprise platform pricing can be hard to justify for a hospital that only needs one or two workflows fixed. Compare software spend against the cost of the manual work still left behind.
Your replacement has to work with the EHR, billing platform, payer portals, and clearinghouse you already rely on. RCM automation fails when the data path is weak.
BAAs, audit logs, access controls, and human review rules matter more than AI branding. Ask how PHI is handled before you ask about extra features.
If the team is already short staffed, choose the option that removes work rather than only giving staff another screen to manage.
A good replacement should shorten turnaround on the workflow that drives denials or reimbursement delays. Faster value matters more than a broad roadmap when a backlog is already hurting cash flow.
For most mid market hospitals and provider groups, the best Olive AI alternative is focused healthcare AI that fixes one costly revenue cycle bottleneck without forcing enterprise pricing. Waystar makes sense for large systems already in that ecosystem, while in house builds only make sense when you have real engineering capacity and time.
Olive AI reportedly raised around $900 million for healthcare automation, then shut down and sold its assets in October 2023. That left many hospitals looking for a safer way to automate prior auth, denials, and intake without depending on one fragile platform.
No. Waystar bought only Olive's data clearinghouse and digital insurance determination units for about $10 million. Humata Health bought the prior auth business, and Availity bought utilization management. Hospitals should evaluate each vendor separately rather than assume one company replaced Olive end to end.
A small or mid sized hospital usually benefits more from focused automation on one or two expensive workflows than from buying a broad enterprise platform. That is where custom healthcare AI often fits better than Waystar pricing.
Start by listing the workflows Olive touched, then collect exports, process maps, user roles, and access details for each system involved. That gives you a clean view of what can be replaced quickly and what needs a larger rebuild.
A single workflow such as prior auth follow up or denial intake can often go live in 4 to 6 weeks when the systems are accessible. Multi workflow programs take longer because security review, testing, and change management are heavier in healthcare.
Only if you already have engineers who understand healthcare integrations, compliance, and production support. Most provider groups get to value faster by targeting one workflow with a managed build instead of staffing a new product team.
We can help you evaluate your options and make the right choice for your organization.